Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience [version 1; peer review: 4 approved]
The GABAergic deficit hypothesis of depression states that a deficit of GABAergic transmission in defined neural circuits is causal for depression. Conversely, an enhancement of GABA transmission, including that triggered by selective serotonin reuptake inhibitors or ketamine, has antidepressant eff...
Main Authors: | Bernhard Lüscher, Hanns Möhler |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2019-05-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/8-751/v1 |
Similar Items
-
Neurosteroids and GABAergic signaling in health and disease
by: MacKenzie Georgina, et al.
Published: (2013-02-01) -
Brexanolone: panacea for postpartum depression? Reply to: ‘Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?’
by: Ajay Kumar Shukla, et al.
Published: (2021-02-01) -
Overview of the Molecular Steps in Steroidogenesis of the GABAergic Neurosteroids Allopregnanolone and Pregnanolone
by: Jennifer J. Liang, et al.
Published: (2018-12-01) -
Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond
by: Charles F. Zorumski, et al.
Published: (2019-11-01) -
Treating Postpartum Depression: What Do We Know about Brexanolone?
by: Muneeza Ali, et al.
Published: (2021-07-01)